Systemic sclerosis & Raynaud's
Serum Type I Interferon Score for Prediction of Clinically Meaningful Disease Progression in Limited Cutaneous Systemic Sclerosis
Authors' conclusion
Serum assessment of type I IFN activity is a valuable predictor of clinically meaningful outcomes in lcSSc.
Study context
- Population
- Patients with limited cutaneous systemic sclerosis (lcSSc) in a national, multicenter observational cohort
- Participants
- 149 patients
- Exposure
- High vs low serum type I interferon (IFN) score
- High IFNn = 67
- Low IFNn = 82reference
- Outcome
- Time to clinical worsening (MINIMISE trial combined Morbi-mortality endpoint)
Methodological detailslongitudinal, national, multicenter observational cohort, time to clinical worsening design, Cox proportional hazard regressions
- Longitudinal
- National, multicenter observational cohort
- Time to clinical worsening design
- Cox proportional hazard regressions
Main finding
As reported in the abstract
TTCW
Hazard ratio (95% CI)P value
High IFNvs Low IFNP for TTCW difference
5.5(2.7–11.3)
P < 0.001IFN score (continuous)independently of clinical variables
2.38(1.4–4.0)
Observational data: associations, not effects.
Further findings
Proportion meeting the endpoint
P < 0.001
Clinical features and time to clinical worsening (TTCW)
- PAH, ILD, digital ulcers and mRSS were associated with TTCW
- These clinical features improve risk stratification over time in combination with IFN score (exploratory)
Original publication
Serum Type I Interferon Score for Prediction of Clinically Meaningful Disease Progression in Limited Cutaneous Systemic Sclerosis. Arthritis Rheumatol. Published 3 March 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →